Figure_S12 from Systematic Engineering of TROP2-Targeted CAR T-Cell Therapy Overcomes Resistance Pathways in Solid Tumors
Elliott J. Brea, Simon Baldacci, Neil Savage, Francesco Facchinetti, Conor Hinchey, Sachiv Chakravarti, Alexis Mottram, Kenneth Ngo, Ha Vo, Brittaney A. Leeper, Bishma Tuladhar, Suthakar Ganapathy, Elena V. Ivanova, Aisha Saldanha, Marie-Anaïs Locquet, Abdulmajeed Salamah, Malcolm Holterhus, Evelyn B. Mesler, Martina De Vizio, Carla Stornante, Marco Campisi, Navin R. Mahadevan, Tran C. Thai, Timothy J. Haggerty, Zehua Li, Cui Nie, Changjing Deng, Xiaoxiao Wang, Louis L. Liu, Thanh U. Barbie, Prafulla C. Gokhale, Cloud P. Paweletz, Anusuya Ramasubramanian, Pasi A. Jänne, David A. Barbie, Eric L. Smith
Cited by 0Open Access
Abstract
<p>Figure S12. In vivo kinetics of CAR infiltration into PC9 subcutaneous tumor. PC9 tumors once established at ∼100 mm3 were injected with either 2.5E6 irrelevantly targeted control or TROP2 CAR+ cells expressing NanoLuciferase, which allows for in vivo tracking of CAR. Mice were imaged after injecting with FFz substrate at indicated time points post CAR engraftment, with right flank representing PC9 mCRD and left flank PC9 mCPD tumor inoculation site.</p>
Related Papers
No related papers found
Powered by citation graph analysis